Ramsay Health Care share price on watch amid Bupa contract termination

Ramsay is playing hardball with Bupa…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Ramsay is terminating its contract with private health insurer Bupa
  • It wants a fairer deal as it battles rising costs and private health insurers watch their profits swell
  • Bupa customers may have to switch health funds to get treatment from Ramsay in the future

The Ramsay Health Care Limited (ASX: RHC) share price will be one to watch on Thursday.

This follows the release of an announcement after the market close today in relation to a contract termination.

Female doctor with a mask holds out hand in a stop gesture.

Image source: Getty Images

Why is the Ramsay share price on watch?

This afternoon Ramsay revealed that it has issued a notice to private health insurance provider Bupa to terminate the Hospital Purchaser Provider Agreement between the two parties.

According to the release, unless a resolution is reached between the parties, Ramsay's contract with Bupa will be terminated with effect from 2 August 2022.

Ramsay appears to believe that private health insurers are not pulling their weight despite accumulating huge profits.

"Costs of providing care have significantly increased for private hospitals over the past two years. On the other hand, health insurers have accumulated profits of $1.8 billion in the calendar year to 31 December 2021," said Ramsay Australia CEO Carmel Monaghan.

What's next?

The release explains that patients booked to be admitted to a Ramsay facility prior to 2 August will not be impacted. After that date, during a legally enforced transitional period, Ramsay will continue to accept benefits paid by Bupa for approved treatments.

However, once the transitional period ends, Bupa insured patients will be required to pay an upfront payment on admission. This will be the difference between the statutory default benefit Bupa is required to pay and Ramsay's hospital treatment costs.

Ms Monaghan said that "Ramsay still hopes to reach agreement with Bupa prior to the contract termination date," but this appears to be far from guaranteed.

The private hospital operator advised that it will be communicating with impacted patients to keep them informed and provide them with options which, in light of the portability rules in the Private Health Insurance Act, include leaving Bupa and changing health funds.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »